[New Product Launch] - Shenzhen Neoimmune Co., Ltd Detection Product: NEO-SH

2023-04-12 10:06:08 neoimmune 28

On April 11, 2023, Pan-In Medical released a new product: NEO-SHM. This product is based on the independent multi-PCR library construction method developed by Shenzhen Neoimmune Co., Ltd. It accurately calculates Ig-SHM (Somatic Hypermutation) through next-generation sequencing (NGS) and provides a basis for prognosis determination in CLL and differential diagnosis in HCL/MCL/SMZL.


图片关键词


Background Introduction


To enhance the efficiency of antigen binding, mutations occur in the IGH gene after B cell maturation, primarily in the IGHV region, known as Somatic Hypermutation (SHM). The IGHV mutation rate represents the ratio of the sequence differences between the clonal cell gene and its homologous germline gene sequence. A rate greater than 2% indicates that the clone has undergone significant SHM.


Product Principle


Shenzhen Neoimmune Co., Ltd's NEO-SHM analysis method is based on the independent development of a multi-PCR library construction technique. By utilizing next-generation sequencing (NGS) technology, the method identifies clonal IgH rearrangements and tumor-specific rearrangement sequences. Additionally, it employs the longest common substring algorithm to assemble and splice based on the overlapping regions of various products, thereby enabling the assembly of a complete IGHV gene sequence from PE150 IgNGS data and the calculation of accurate SHM.


图片关键词




Clinical Significance


图片关键词



Data Support


图片关键词



Comparison of Detection Technologies

图片关键词





Contact Us

8/F, Block A, Hengtemei Building, No. 3 Ganli Road, Longgang District, Shenzhen; 402, Kelente R&D Building, Ganli Road, Longgang District, Shenzhen.

TEL: 0755-8453-4802

EMAIL

query@neoimmune.cn